PROMISE Framework for Standardized PET Imaging of Prostate Cancer
The Prostate Cancer Molecular Imaging Standardized Evaluation
(PROMISE) criteria, established in 2018 and revised in 2023, serve as guide for interpreting PSMA-PET scans. These scans are advanced diagnostic tools that identify prostate cancer and its dissemination throughout the body.
Why is PROMISE needed?
~
- Identifying whether the cancer has metastasized to other body regions.
- Detecting the recurrence of prostate cancer following surgery or radiation therapy.
- Assessing suitability for PSMA-targeted prostate cancer treatments.
The PROMISE system organizes information from PSMA-PET scans to facilitate accurate and clear communication between physicians and imaging centers.
How PROMISE works
~
The PROMISE system classifies the state of disease in a PSMA-PET scan by categorizing it into specific regions: local (T), lymph node (N), and organ (M) spread. Disease extent and location is reported for all body regions and summarized in a comprehensive diagnosis code.
 | Pocket Card on PROMISE Pocket Card for Standardized PSMA-PET reporting PROMISE Pocket Card.pdf (212.66KB) |
Pocket Card for Standardized PSMA-PET reporting
| PROMISE Pocket Card.pdf (212.66KB) |
PROMISE PET Registry
~
PSMA-PET imaging and the PROMISE framework are linked to prostate cancer outcomes. To deepen our understanding of the relationship between PET imaging results and patient survival rates, we have established a global registry that invites the participation of PET imaging centers worldwide.
This registry is open to all imaging centers that utilize PSMA-PET for a range of prostate cancer diagnoses and possess data on patient overall survival. These centers are encouraged to contribute to our collective knowledge base.
If you are a medical professional interested in contributing to the PROMISE PET registry, please reach out.